Increased retinal neovascularization in Fas ligand-deficient mice

Investigative Ophthalmology and Visual Science

Volumn 44, Issue 7, 2003, Pages 3202-3210

  Davies, Michael H ^b   Eubanks, Joshua P ^b   Powers, Michael R ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGEN ANTIBODY; COLLAGEN TYPE 4; FAS ANTIGEN; FAS LIGAND; OXYGEN; RNA;

ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY LABELING; APOPTOSIS; ARTICLE; CONTROLLED STUDY; ELECTRON MICROSCOPY; FLUORESCENCE MICROSCOPY; IMMUNOHISTOCHEMISTRY; MOUSE; NICK END LABELING; NONHUMAN; PRIORITY JOURNAL; RETINA BLOOD VESSEL; RETINA FLUORESCEIN ANGIOGRAPHY; RETINA NEOVASCULARIZATION; RETINOPATHY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ANIMALS; ANTIGENS, CD95; APOPTOSIS; DISEASE MODELS, ANIMAL; FAS LIGAND PROTEIN; FLUORESCEIN ANGIOGRAPHY; HUMANS; HYPEROXIA; IN SITU NICK-END LABELING; INFANT, NEWBORN; LIGANDS; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED C57BL; MICE, MUTANT STRAINS; MICROSCOPY, FLUORESCENCE; RETINAL NEOVASCULARIZATION; RETINAL VESSELS; RETINOPATHY OF PREMATURITY; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 0037900474     PISSN: 01460404     EISSN: None     Source Type: Journal    
DOI: 10.1167/iovs.03-0050     Document Type: Article

References (39)

1. Smith LE, Wesolowski E, McLellan A, et al. Oxygen-induced retinopathy in the mouse. Invest Ophthalmol Vis Sci. 1994;35:101-111.
2. Barinapa M. Shedding light on blindness. Science. 1995;267:452-453.
3. McLeod DS, Brownstein R, Lutty GA. Vaso-obliteration in the canine model of oxygen-induced retinopathy. Invest Ophthalmol Vis Sci. 1996;37:300-311.
4. Connolly SE, Hores TA, Smith LE, D'Amore PA. Characterization of vascular development in the mouse retina. Microvasc Res. 1988;36:275-290.
5. Penn JS, Johnson BD. Fluorescein angiography as a means of assessing retinal vascular pathology in oxygen-exposed newborn rats. Curr Eye Res. 1993;12:561-570.
6. Ashton N. Oxygen and the growth and development of retinal vessels. In vivo and in vitro studies. The XX Francis I. Proctor Lecture. Am J Ophthalmol. 1966;62:412-435.
7. Flynn JT, O'Grady GE, Herrera J, Kushner BJ, Cantolino S, Milam W. Retrolental fibroplasia: I. Clinical observations. Arch Ophthalmol. 1977;95:217-223.
8. Alon T, Hemo I, Itin A, Pe'er J, Stone J, Keshet E. Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity. Nat Med. 1995;1:1024-1028.
9. Walczak H, Krammer PH. The CD95 (APO-1/Fas) and the TRAIL (APO-2L) apoptosis systems. Exp Cell Res. 2000;256:58-66.
10. Nagata S, Golstein P. The Fas death factor. Science. 1995;267:1449-1456.
11. Suda T, Takahashi T, Golstein P, Nagata S. Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family. Cell. 1993;75:1169-1178.
12. Cardier JE, Schulte T, Kammer H, Kwak J, Cardier M. Fas (CD95, APO-1) antigen expression and function in murine liver endothelial cells: implications for the regulation of apoptosis in liver endothelial cells. FASEB J. 1999;13:1950-1960.
13. von Boehmer H. Positive selection of lymphocytes. Cell. 1994;76:219-228.
14. Gratas C, Tohma Y, Van Meir EG, et al. Fas ligand expression in glioblastoma cell lines and primary astrocytic brain tumors. Brain Pathol. 1997;7:863-869.
15. Kondo T, Suda T, Fukuyama H, Adachi M, Nagata S. Essential roles of the Fas ligand in the development of hepatitis. Nat Med. 1997;3:409-413.
16. Kaplan HJ, Leibole MA, Tezel T, Ferguson TA. Fas ligand (CD95 ligand) controls angiogenesis beneath the retina. Nat Med. 1999;5:292-297.
17. Wilson SE. Stimulus-specific and cell type-specific cascades: emerging principles relating to control of apoptosis in the eye. Exp Eye Res. 1999;69:255-266.
18. Griffith TS, Brunner T, Fletcher SM, Green DR, Ferguson TA. Fas ligand-induced apoptosis as a mechanism of immune privilege. Science. 1995;270:1189-1192.
19. Hu MS, Schwartzman JD, Yeaman GR, et al. Fas-FasL interaction involved in pathogenesis of ocular toxoplasmosis in mice. Infect Immun. 1999;67:928-935.
20. Takahashi T, Tanaka M, Brannan CI, et al. Generalized lymphoproliferative disease in mice, caused by a point mutation in the Fas ligand. Cell. 1994;76:969-976.
21. D'Amato R, Wesolowski E, Smith LE. Microscopic visualization of the retina by angiography with high-molecular-weight fluorescein-labeled dextrans in the mouse. Microvasc Res. 1993;46:135-142.
22. Morrison JC, Nylander KB, Lauer AK, Cepurna WO, Johnson E. Glaucoma drops control intraocular pressure and protect optic nerves in a rat model of glaucoma. Invest Ophthalmol Vis Sci. 1998;39:526-531.
23. Rosenbaum JT, Han YB, Park JM, Kennedy M, Planck SR. Tumor necrosis factor-alpha is not essential in endotoxin induced eye inflammation: studies in cytokine receptor deficient mice. J Rheumatol. 1998;25:2408-2416.
24. Penn JS, Tolman BL, Lowery LA. Variable oxygen exposure causes preretinal neovascularization in the newborn rat. Invest Ophthalmol Vis Sci. 1993;34:576-585.
25. Sata M, Walsh K. Oxidized LDL activates fas-mediated endothelial cell apoptosis. J Clin Invest. 1998;102:1682-1689.
26. Volpert OV, Zaichuk T, Zhou W, et al. Inducer-stimulated Fas targets activated endothelium for destruction by anti-angiogenic thrombospondin-1 and pigment epithelium-derived factor. Nat Med. 2002;8:349-357.
27. Robaye B, Mosselmans R, Fiers W, Dumont JE, Galand P. Tumor necrosis factor induces apoptosis (programmed cell death) in normal endothelial cells in vitro. Am J Pathol. 1991;138:447-453.
28. Wiley SR, Schooley K, Smolak PJ, et al. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity. 1995;3:673-682.
29. Fruttiger M. Development of the mouse retinal vasculature: angiogenesis versus vasculogenesis. Invest Ophthalmol Vis Sci. 2002;43:522-527.
30. Thomas WE. Brain macrophages: evaluation of microglia and their functions. Brain Res Brain Res Rev. 1992;17:61-74.
31. Carmeliet P. Mechanisms of angiogenesis and arteriogenesis. Nat Med. 2000;6:389-395.
32. Sata M, Walsh K. Endothelial cell apoptosis induced by oxidized LDL is associated with the down-regulation of the cellular caspase inhibitor FLIP. J Biol Chem. 1998;273:33103-33106.
33. Walsh K, Sata M. Is extravasation a Fas-regulated process? Mol Med Today. 1999;5:61-67.
34. Freyberg MA, Kaiser D, Graf R, Friedl P. Vascular endothelial cells express a functional fas-receptor due to lack of hemodynamic forces. Apoptosis. 2001;6:339-343.
35. Pierce EA, Avery RL, Foley ED, Aiello LP, Smith LE. Vascular endothelial growth factor/vascular permeability factor expression in a mouse model of retinal neovascularization. Proc Natl Acad Sci USA. 1995;92:905-909.
36. Benjamin LE, Golijanin D, Itin A, Pode D, Keshet E. Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal. J Clin Invest. 1999;103:159-165.
37. Doll JA, Reiher FK, Crawford SE, Pins MR, Campbell SC, Bouck NP. Thrombospondin-1, vascular endothelial growth factor and fibroblast growth factor-2 are key functional regulators of angiogenesis in the prostate. Prostate. 2001;49:293-305.
38. Walsh K, Sata M. Negative regulation of inflammation by Fas ligand expression on the vascular endothelium. Trends Cardiovasc Med. 1999;9:34-41.
39. Fulton AB, Hansen RM. Photoreceptor function in infants and children with a history of mild retinopathy of prematurity. J Opt Soc Am A. 1996;13:566-571.